| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283074 | Clinical Gastroenterology and Hepatology | 2012 | 6 Pages |
Abstract
Most patients with moderate-severe IBD evaluated in an outpatient practice would not qualify for enrollment in a pivotal RCT of biological reagents; this finding raises important questions about their therapeutic efficacy beyond the clinical trial populations. Additional evaluation of the transparency of RCT design and selection criteria is needed to determine whether trial results can be generalized to the population.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Christina Ha, Thomas A. Ullman, Corey A. Siegel, Asher Kornbluth,